{"id":90047,"date":"2025-10-18T21:00:08","date_gmt":"2025-10-18T19:00:08","guid":{"rendered":"https:\/\/port.lukasiewicz.gov.pl\/?post_type=projects&p=90047"},"modified":"2026-03-16T12:40:05","modified_gmt":"2026-03-16T11:40:05","slug":"analysis-of-the-effectiveness-of-glioma-immunotherapy-using-gamma-delta-t-lymphocytes-glejak","status":"publish","type":"projects","link":"https:\/\/port.lukasiewicz.gov.pl\/en\/projekty-badawcze\/analysis-of-the-effectiveness-of-glioma-immunotherapy-using-gamma-delta-t-lymphocytes-glejak\/","title":{"rendered":"Analysis of the Effectiveness of Glioma Immunotherapy Using Gamma-Delta T Lymphocytes – Glejak"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Project funded by the National Science Centre (NCN)<\/strong> under the \u201cOPUS-18\u201d<\/strong> competition<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"NCN\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Project number:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Project value:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t3 374 760,00 PLN\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Project implementation period:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t28\/07\/2020 \u2013 27\/07\/2027\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Project manager:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tDr. hab. Grzegorz Chodaczek\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tVIEW PROJECT<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The glioblastoma multiforme (GBM)<\/strong> is the most common malignant brain tumor<\/strong> with a very poor prognosis<\/strong> and a median survival of approximately 10 months<\/strong>. Current treatment methods, including surgery, radiotherapy, and chemotherapy, show low efficacy<\/strong>, as tumor cells survive in about 90% of cases<\/strong>. These statistics highlight the urgent need for more effective therapeutic approaches<\/strong> in GBM treatment.<\/p>

A promising direction in oncology is immunotherapy<\/strong>\u2014a therapeutic approach that harnesses the body\u2019s own immune cells<\/strong> to recognize and eliminate cancer cells. Among immune cells with anti-tumor potential<\/strong>, a particularly interesting group are T lymphocytes<\/strong> possessing a T cell receptor (TCR)<\/strong> composed of \u03b3 and \u03b4 chains<\/strong>, known as \u03b3\u03b4 T cells<\/strong>.<\/p>

In humans, two major \u03b3\u03b4 T cell populations are recognized:<\/p>

  • V\u03b42+ cells<\/strong>, predominant in peripheral blood<\/strong>, and<\/p><\/li>

  • V\u03b41+ cells<\/strong>, found mainly in peripheral tissues<\/strong>.<\/p><\/li><\/ul>

    Both populations can recognize tumor-associated<\/strong> and stress-induced antigens<\/strong>, enabling them to mount a cytotoxic response<\/strong> against cancer cells. So far, preclinical studies<\/strong> using mouse models of GBM have successfully tested V\u03b42+ cells<\/strong> expanded in vitro<\/strong>, but these experiments lacked a human tumor microenvironment<\/strong>\u2014including patient-derived immune cells<\/strong> that can suppress anti-tumor responses.<\/p>

    This project aims to compare the effector functions<\/strong> of V\u03b41+ and V\u03b42+ \u03b3\u03b4 T cells<\/strong> against glioma cells to determine which population holds the greatest therapeutic potential<\/strong> for immunotherapy<\/strong>.<\/p>

    Through collaboration with neurosurgeons from the Wroclaw Medical University<\/strong>, glioma tissue samples<\/strong> resected from patients will be used to characterize the cytotoxic activity<\/strong> of \u03b3\u03b4 T cells in vitro<\/strong> and in vivo<\/strong>. The in vivo studies<\/strong> will employ humanized mouse models<\/strong>, which better replicate the human tumor microenvironment<\/strong>, allowing more accurate assessment of \u03b3\u03b4 T cell-based therapies.<\/p>

    The results of this project are expected to advance the understanding<\/strong> of \u03b3\u03b4 T cell functions<\/strong> in glioma and may contribute to the development of novel, effective immunotherapeutic strategies<\/strong> for treating glioblastoma multiforme (GBM)<\/strong>.<\/p><\/div><\/div><\/div><\/div>

    \u00a0<\/div>
    \u00a0<\/div><\/div><\/div><\/div><\/article>
    \u00a0<\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Project funded by the National Science Centre (NCN) under the \u201cOPUS-18\u201d competition Project number: Project value: Project implementation period: Project manager: VIEW PROJECT The glioblastoma multiforme (GBM) is the most common malignant brain tumor with a very poor prognosis and a median survival of approximately 10 months. Current treatment methods, including surgery, radiotherapy, and chemotherapy, […]<\/p>\n","protected":false},"featured_media":94100,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","inline_featured_image":false,"footnotes":""},"categories":[747],"grupy_badawcze":[614],"pozostale_projekty":[],"class_list":["post-90047","projects","type-projects","status-publish","format-standard","has-post-thumbnail","hentry","category-nsc","grupy_badawcze-grupa-badawcza-immunoterapii"],"acf":{"kierownik_projektu":["Dr. hab. Grzegorz Chodaczek"],"dofinansowanie":"Narodowe Centrum Nauki","grupa_badawcza":["Immunotherapy Research Group"],"nazwa_projektu":"3 374 760,00 PLN","tematyka_projektu":"28\/07\/2020 \u2013 27\/07\/2027","opis_projektu":"","dofinanowanie":"National Science Centre","nr_projektu":"UMO-2019\/35\/B\/NZ6\/03748","wartosc_dofinansowania":"2 895 000,00 PLN"},"publishpress_future_action":{"enabled":true,"date":"2026-07-27 00:00:00","action":"category","newStatus":"draft","terms":[595],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/90047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects"}],"about":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/types\/projects"}],"version-history":[{"count":5,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/90047\/revisions"}],"predecessor-version":[{"id":98557,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/projects\/90047\/revisions\/98557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media\/94100"}],"wp:attachment":[{"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/media?parent=90047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/categories?post=90047"},{"taxonomy":"grupy_badawcze","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/grupy_badawcze?post=90047"},{"taxonomy":"pozostale_projekty","embeddable":true,"href":"https:\/\/port.lukasiewicz.gov.pl\/en\/wp-json\/wp\/v2\/pozostale_projekty?post=90047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}